Deregulation of the IGF axis in cancer: Epidemiological evidence and potential therapeutic interventions

Endocrine-Related Cancer

Volumn 10, Issue 4, 2003, Pages 561-578

  Jerome, L ^a   Shiry, L ^b   Leyland Jones, B ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Insmed Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN; NAKIJIQUINONE DERIVATIVE; PACLITAXEL; PEGVISOMANT; PROTEIN TYROSINE KINASE INHIBITOR; SILIBININ; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CIRCULATION; COLON CANCER; DEREGULATION; DOSE RESPONSE; DRUG MECHANISM; DRUG SCREENING; EPIDEMIOLOGICAL DATA; HORMONAL REGULATION; HUMAN; LUNG CANCER; NONHUMAN; PROSTATE CANCER; PROTEIN BINDING; PROTEIN TARGETING; REVIEW;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 0347087571     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100561     Document Type: Review

References (197)

1. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL & Carbone DP 2002 Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 123 1191-1204.
2. Arai T, Busby W Jr & Clemmons DR 1996 Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 137 4571-4575.
3. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ & Hill DJ 1994 Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. Journal of Clinical Endocrinology and Metabolism 79 1871-1876.
4. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC & Osborne CK 1989 Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. Journal of Clinical Investigation 84 1418-1423.
5. Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F & Taketani Y 1997 Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocrine Journal 44 419-424.
6. Bari D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA & Fraumeni JF Jr 2002 Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes and Control 13 395-400.
7. Barreca A, Artini PG, Cesarone A, Arvigo M, D'Ambrogio G, Genazzani AR, Giordano G & Minuto F 1996 Interrelationships between follicle stimulating hormone and the growth hormone-insulin-like growth factor-IGF-binding proteins axes in human granulosa cells in culture. Journal of Endocrinological Investigation 19 35-42.
8. Baxter RC 1994 Insulin-like growth factor binding proteins in the human circulation: a review. Hormone Research 42 140-144.
9. Baxter RC 2001 Signaling pathways involved in antiproliferative effects of IGFBP-3: a review. Molecular Pathology 54 145-148.
10. Beech DJ, Parekh N & Pang Y 2001 Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncology Reports 8 325-329.
11. Benini S, Manara MC, Baldini N, Cerisano V, Massimo S, Mercuri M, Lollini PL, Nanni P, Picci P & Scotlandi K 2001 Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clinical Cancer Research 7 1790-1797.
12. Bernard L, Babajko S, Binoux M & Ricort JM 2002 The amino-terminal region of insulin-like growth factor binding protein-3, induces apoptosis of MCF-7 breast carcinoma cells. Biochemical and Biophysical Research Communications 293 55-60.
13. Blum G, Gazit A & Levitzki A 2000 Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39 15705-15712.
14. Booth BA, Boes M & Bar RS 1996 IGFBP-3 proteolysis by plasmin, thrombin, serum: heparin binding, IGF binding, and structure of fragments. American Journal of Physiology 271 E465-E470.
15. Boyle BJ, Zhao XY, Cohen P & Feldman D 2001 Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. Journal of Urology 165 1319-1324.
16. Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M & Armatis P 2002 Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95 1735-1745.
17. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR & Kley N 1995 Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377 646-649.
18. Butt AI, Firth SM, King MA & Baxter RC 2000 Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. Journal of Biological Chemistry 275 39174-39181.
19. Butt AJ, Fraley KA, Firth SM & Baxter RC 2002 IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology 143 2693-2699.
20. Campbell MJ, Woodside JV, Secker-Walker J, Titcomb A & Leathem AJ 2001 IGF status is altered by tamoxifen in patients with breast cancer. Molecular Pathology 54 307-310.
21. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563-566.
22. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M & Giovannucci E 2002 Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute 94 1099-1106.
23. Chang YS, Kong G, Sun S, Liu D, El Naggar AK, Khuri FR, Hong WK, Lee HY & Gong K 2002a Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clinical Cancer Research 8 3796-3802.
24. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR & Lee HY 2002b Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clinical Cancer Research 8 3669-3675.
25. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P & Bajo AM 2001 Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Journal of Cancer Research and Clinical Oncology 127 645-652.
26. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr & Hsing AW 2001 Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiology, Biomarkers and Prevention 10 421-427.
27. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL & Rosenfeld RG 1994 Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism 79 1410-1415.
28. Collett-Solberg PF & Cohen P 2000 Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine 12 121-136.
29. Colston KW, Perks CM, Xie SP & Holly JM 1998 Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. Journal of Molecular Endocrinology 20 157-162.
30. Conover CA & Powell DR 1991 Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology 129 710-716.
31. Coverley JA, Martin JL & Baxter RC 2000 The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology 141 564-570.
32. Csernus VJ, Schally AV, Kiaris H & Armatis P 1999 Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. PNAS 96 3098-3103.
33. Cui H, Horon IL, Ohlsson R, Hamilton SR & Feinberg AP 1998 Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nature Medicine 4 1276-1280.
34. D'Ambrosio C, Ferber A, Resnicoff M & Baserga R 1996 A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Research 56 4013-4020.
35. DeChiara TM, Efstratiadis A & Robertson EJ 1990 A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345 78-80.
36. Delbe J, Blat C, Desauty G & Harel L 1991 Presence of IDF45 (mlGFBP-3) binding sites on chick embryo fibroblasts. Biochemical and Biophysical Research Communications 179 495-501.
37. Dennis PA & Rifkin DB 1991 Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. PNAS 88 580-584.
38. Devi GR, De Souza AT, Byrd JC, Jirtle RL & MacDonald RG 1999 Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. Cancer Research 59 4314-4319.
39. Devi GR, Sprenger CC, Plymate SR & Rosenfeld RG 2002 Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 51 141-152.
40. Dokmanovic M, Chang BD, Fang J & Roninson IB 2002 Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes. Cancer Biology and Therapy 1 24-27.
41. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R & Barrett JC 1998 A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Research 58 3353-3361.
42. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B & Pommier G 1994 Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. International Journal of Cancer 57 491-497.
43. Ellis MJ, Leav BA, Yang Z, Rasmussen A, Pearce A, Zweibel JA, Lippman ME & Cullen KJ 1996 Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells. Molecular Endocrinology 10 286-297.
44. Fielder PJ, Rosenfeld RG, Graves HC, Grandbois K, Maack CA, Sawamura S, Ogawa Y, Sommer A & Cohen P 1994 Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regulation 4 164-172.
45. Firth SM & Baxter RC 1999 Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. Journal of Endocrinology 160 379-387.
46. Firth SM & Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews 23 824-854.
47. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L & Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 1371-1388.
48. Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR & Holly JM 2000 Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. International Journal of Cancer 88 448-453.
49. Fowlkes JL, Enghild JJ, Suzuki K & Nagase H 1994 Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. Journal of Biological Chemistry 269 25742-25746.
50. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278-3288.
51. Frattali AL & Pessin JE 1993 Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. Journal of Biological Chemistry 268 7393-7400.
52. Furstenberger G & Senn HJ 2002 Insulin-like growth factors and cancer. Lancet Oncology 3 298-302.
53. Gill ZP, Perks CM, Newcomb PV & Holly JM 1997 Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. Journal of Biological Chemistry 272 25602-25607.
54. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE & Hankinson SE 2000 A prospective study of plasma insulin-like growth factor-I and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiology, Biomarkers and Prevention 9 345-349.
55. Giuliano M, Lauricella M, Vassallo E, Carabillo M, Vento R & Tesoriere G 1998 Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Investigative Ophthalmology and Visual Science 39 1300-1311.
56. Grimberg A & Cohen P 2000 Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. Journal of Cellular Physiology 183 1-9.
57. Gucev ZS, Oh Y, Kelley KM & Rosenfeld RG 1996 Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Research 56 1545-1550.
58. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, Yumoto E, Higashi T & Tsuji T 2002 Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Letters 176 149-158.
59. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE & Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 1393-1396.
60. Harman SM, Metter EJ, Blackman MR, Landis PK & Carter HB 2000 Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. Journal of Clinical Endocrinology and Metabolism 85 4258-4265.
61. Hasegawa T, Cohen P, Hasegawa Y, Fielder PJ & Rosenfeld RG 1995 Characterization of the insulin-like growth factors (IGF) axis in a cultured mouse Leydig cell line (TM-3). Growth Regulation 5 151-159.
62. Hochscheid R, Jaques G & Wegmann B 2000 Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. Journal of Endocrinology 166 553-563.
63. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D & Holly JM 2000 IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. International Journal of Cancer 88 336-341.
64. Huynh H, Chow PK, Ooi LL & Soo KC 2002 A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth and Differentiation 13 115-122.
65. Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT & Havemann K 1997 Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 138 1767-1770.
66. Jarrard DF, Bussemakers MJ, Bova GS & Isaacs WB 1995 Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clinical Cancer Research 1 1471-1478.
67. Jenkins PJ 2000 Acromegaly and colon cancer. Growth Hormone and IGF Research 10 (Suppl) S35-S36.
68. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, Wass JA & Besser M 1997 Acromegaly, colonic polyps and carcinoma. Clinical Endocrinology 47 17-22.
69. Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB, Monson JP & Besser GM 2000 Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. Journal of Clinical Endocrinology and Metabolism 85 3218-3221.
70. Jones JI & Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 16 3-34.
71. Jones JI, D'Ercole AJ, Camacho-Hubner C & Clemmons DR 1991 Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. PNAS 88 7481-7485.
72. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P & Halmos G 1997a Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. PNAS 94 5810-5813.
73. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P & Vadillo-Buenfil M 1997b Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. British Journal of Cancer 75 1585-1592.
74. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J & Armatis P 1998 Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer 82 909-917.
75. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G & Hallmans G 2002 Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes and Control 13 307-316.
76. Kahan Z, Varga JL, Schally AV, Rekasi Z, Armatis P, Chatzistamou L, Czompoly T & Halmos G 2000 Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Research and Treatment 60 71-79.
77. Kaleko M, Rutter WJ & Miller AD 1990 Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Molecular and Cellular Biology 10 464-473.
78. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J & Sharoni Y 1997 Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in Ishikawa endometrial cancer cells. Journal of Biological Chemistry 272 16514-16520.
79. Katsaros D, Yu H, Piccinno R, Puopolo M, Rigault de la Longrais IA, Fracchioli S & Massobrio M 2002 Expression and prognostic significance in epithelial ovarian cancer. Minerva Ginecologica 54 15-24.
80. Khandwala HM, McCutcheon IE, Flyvbjerg A & Friend KE 2000 The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews 21 215-244.
81. Kiaris H, Schally AV, Varga JL, Groot K & Armatis P 1999 Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. PNAS 96 14894-14898.
82. Kiaris H, Schally AV & Varga JL 2000 Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2 242-250.
83. Kim HT, Choi BH, Niikawa N, Lee TS & Chang SI 1998 Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. American Journal of Medical Genetics 80 391-395.
84. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ & Cuatrecasas P 1983 Monoclonal antibodies to receptors for insulin and somatomedin-C. Journal of Biological Chemistry 258 6561-6566.
85. Lalou C, Silve C, Rosato R, Segovia B & Binoux M 1994 Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 135 2318-2326.
86. Lalou C, Lassarre C & Binoux M 1996 A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137 3206-3212.
87. Lalou C, Sawamura S, Segovia B, Ogawa Y & Binoux M 1997 Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity. Comptes Rendus de l'Academie des Sciences. Serie III, Sciences de la Vie 320 621-628.
88. Lamberts SW, van der Lely AJ, de Herder WW & Hofland LJ 1996 Octreotide. New England Journal of Medicine 334 246-254.
89. Lamharzi N, Schally AV, Koppan M & Groot K 1998 Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. PNAS 95 8864-8868.
90. Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P & Stewart CL 1994 Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes and Development 8 2953-2963.
91. Leal SM, Liu Q, Huang SS & Huang JS 1997 The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. Journal of Biological Chemistry 272 20572-20576.
92. Lee CT, Park KH, Adachi Y, Seol JY, Yoo CG, Kim YW, Han SK, Shim YS, Coffee K, Dikov MM & Carbone DP 2003 Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Therapy 10 57-63.
93. Lee DY, Yi HK, Hwang PH & Oh Y 2002 Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells. Biochemical and Biophysical Research Communications 294 480-486.
94. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P & Kurie JM 2002 Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Research 62 3530-3537.
95. LeRoith D & Roberts CT 2003 The insulin-like growth factor system and cancer. Cancer Letters 195 127-137.
96. Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M & Yu H 2001 Free insulin-like growth factor-I and breast cancer risk. International Journal of Cancer 91 736-739.
97. Li SL, Liang SJ, Guo N, Wu AM & Fujita-Yamaguchi Y 2000 Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunology and Immunotherapy 49 243-252.
98. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R & Keller GA 1997 Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 138 1763-1766.
99. Li YM, Schacher DH, Liu Q, Arkins S, Rebeiz N, McCusker RH Jr, Dantzer R & Kelley KW 1997 Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 138 362-368.
100. Liebow C, Reilly C, Serrano M & Schally AV 1989 Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. PNAS 86 2003-2007.
101. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM & Cohen P 2000 Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. Journal of Biological Chemistry 275 33607-33613.
102. Liu JP, Baker J, Perkins AS, Robertson EJ & Efstratiadis A 1993 Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and type 1 IGF receptor (IGF1R). Cell 75 59-72.
103. London SJ, Yuan JM, Travlos GS, Gao YT, Wilson RE, Ross RK & Yu MC 2002 Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. Journal of the National Cancer Institute 94 749-754.
104. Lu Y, Zi X, Zhao Y, Mascarenhas D & Pollak M 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute 93 1852-1857.
105. Lucas T, Astorga R & Catala M 2003 Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clinical Endocrinology 58 471-481.
106. Ludwig T, Eggenschwiler J, Fisher P, D'Ercole AJ, Davenport ML & Efstratiadis A 1996 Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in IGF2 and IGF1R null backgrounds. Developmental Biology 177 517-535.
107. Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore RE, Riboli E, Rinaldi S & Kaaks R 2001 A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. International Journal of Cancer 92 888-892.
108. Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E & Kaaks R 2002 Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. International Journal of Cancer 101 549-554.
109. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH & Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute 91 620-625.
110. Macaulay VM 1992 Insulin-like growth factors and cancer. British Journal of Cancer 65 311-320.
111. Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V, Marra E & Perlino E 2000 Insulin-like growth factor 1 expression in thyroid tumors. Applied Immunohistochemistry and Molecular Morphology 8 110-119.
112. Manni A, Badger B, Wei L, Zaenglein A, Grove R, Khin S, Heitjan D, Shimasaki S & Ling N 1994 Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Research 54 2934-2942.
113. Martin JL, Weenink SM & Baxter RC 2003 Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases. Journal of Biological Chemistry 278 2969-2976.
114. McCaig C, Fowler CA, Laurence NJ, Lai T, Savage PB, Holly JM & Perks CM 2002 Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. British Journal of Cancer 86 1963-1969.
115. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA & Friend KE 2001 Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. Journal of Neurosurgery 94 487-492.
116. Miyata Y, Sakai H, Hayashi T & Kanetake H 2003 Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54 125-132.
117. Morrione A, DeAngelis T & Baserga R 1995 Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. Journal of Virology 69 5300-5303.
118. Moschos SJ & Mantzoros CS 2002 The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63 317-332.
119. Murakami K, Matsuura T, Hasumura S, Nagamori S, Yamada Y & Saiki I 2000 Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation. Cancer Letters 151 63-70.
120. Nolan CM, Kyle JW, Watanabe H & Sly WS 1990 Binding of insulin-like growth factor II (IGF-II) by human cation-independent mannose 6-phosphate receptor/IGF-II receptor expressed in receptor-deficient mouse L cells. Cell Regulation 1 197-213.
121. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B & Ellis MJ 1998 The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Research and Treatment 47 269-281.
122. Oda H, Shimizu S, Minami K, Kaneko K & Ishikawa T 1997 Loss of imprinting of the IGF2 gene in a Wilms' tumor in an adult. Journal of the National Cancer Institute 89 1813-1814.
123. Oh Y 1998 IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Research and Treatment 47 283-293.
124. Oh Y, Muller HL, Pham H & Rosenfeld RG 1993 Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. Journal of Biological Chemistry 268 26045-26048.
125. Okabe E, Kajihara J, Usami Y & Hirano K 1999 The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3. FEBS Letters 447 87-90.
126. Olivecrona H, Hilding A, Ekstrom C, Barle H, Nyberg B, Moller C, Delhanty PJ, Baxter RC, Angelin B, Ekstrom TJ & Tally M 1999 Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. Journal of Clinical Endocrinology and Metabolism 84 553-560.
127. Orme SM, McNally RJ, Cartwright RA & Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 83 2730-2734.
128. Osborne CK 1998 Tamoxifen in the treatment of breast cancer. New England Journal of Medicine 339 1609-1618.
129. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R & Belfiore A 2002 Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. Journal of Biological Chemistry 277 39684-39695.
130. Parker AS, Cheville JC, Janney CA & Cerhan JR 2002 High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Human Pathology 33 801-805.
131. Perks CM, McCaig C & Holly JM 2000 Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. Journal of Cellular Biochemistry 80 248-258.
132. Perks CM, McCaig C, Clarke JB, Clemmons DR & Holly JM 2002 A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochemical and Biophysical Research Communications 294 988-994.
133. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M & Armatis P 1995 Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. Journal of the National Cancer Institute 87 1787-1794.
134. Pollak MN, Polychronakos C & Guyda H 1989 Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Research 9 889-891.
135. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK & Yu MC 2001 IGF-I, IGF-II and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. British Journal of Cancer 85 1695-1699.
136. Rajah R, Katz L, Nunn S, Solberg P, Beers T & Cohen P 1995 Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Progress in Growth Factor Research 6 273-284.
137. Rajah R, Valentinis B & Cohen P 1997 Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-betal on programmed cell death through a p53- and IGF-independent mechanism. Journal of Biological Chemistry 272 12181-12188.
138. Rajah R, Khare A, Lee PD & Cohen P 1999 Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. Journal of Endocrinology 163 487-494.
139. Rajah R, Lee KW & Cohen P 2002 Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth and Differentiation 13 163-171.
140. Reiss K, D'Ambrosio C, Tu X, Tu C & Baserga R 1998 Inhibition of
141. Renehan AG, Jones J, Potten CS, Shalet SM & O'Dwyer ST 2000a Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. British Journal of Cancer 83 1344-1350.
142. Renehan AG, Painter JE, O'Halloran D, Atkin WS, Potten CS, O'Dwyer ST & Shalet SM 2000b Circulating insulin-like growth factor II and colorectal adenomas. Journal of Clinical Endocrinology and Metabolism 85 3402-3408.
143. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P & Baserga R 1995 The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Research 55 2463-2469.
144. Resnicoff M, Tjuvajev J, Rotman HL, Abraham D, Curtis M, Aiken R & Baserga R 1996 Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. Journal of Experimental Therapeutics and Oncology 1 385-389.
145. Ricort JM & Binoux M 2001 Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology 142 108-113.
146. Rodriguez-Tarduchy G, Collins MK, Garcia I & Lopez-Rivas A 1992 Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. Journal of Immunology 149 535-540.
147. Rozen F, Zhang J & Pollak M 1998 Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. International Journal of Oncology 13 865-869.
148. Rubin R & Baserga R 1995 Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Laboratory Investigation 73 311-331.
149. Sachdev D & Yee D 2001 The IGF system and breast cancer. Endocrine-Related Cancer 8 197-209.
150. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS & Yee D 2003 A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Research 63 627-635.
151. Salahifar H, Firth SM, Baxter RC & Martin JL 2000 Characterization of an amino-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells. Growth Hormone and IGF Research 10 367-377.
152. Samani AA & Brodt P 2001 The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surgical Oncology Clinics of North America 10 289-312, viii.
153. Schally AV & Varga JL 1999 Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends in Endocrinology and Metabolism 10 383-391.
154. Schedlich LJ, Young TF, Firth SM & Baxter RC 1998 Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. Journal of Biological Chemistry 273 18347-18352.
155. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA & Baxter RC 2000 Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. Journal of Biological Chemistry 275 23462-23470.
156. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R & Belfiore A 1999 Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18 2471-2479.
157. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R & Belfiore A 2002 In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21 8240-8250.
158. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, Picci P, Manara MC & Baldini N 1996 Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Research 56 4570-4574.
159. Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P & Baldini N 1998 Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Research 58 4127-4131.
160. Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, Perdichizzi S, Lollini PL, De Giovanni C, Landuzzi L & Picci P 2002a Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. International Journal of Cancer 101 11-16.
161. Scotlandi K, Maini C, Manara MC, Benini S, Serra M, Cerisano V, Strammiello R, Baldini N, Lollini PL, Nanni P, Nicoletti G & Picci P 2002b Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Therapy 9 296-307.
162. Seely BL, Samimi G & Webster NJ 2002 Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer 2 15.
163. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A & Baserga R 1993 Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. PNAS 90 11217-11221.
164. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A & Baserga R 1994 Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Molecular and Cellular Biology 14 3604-3612.
165. Sepp-Lorenzino L 1998 Structure and function of the insulin-like growth factor I receptor. Breast Cancer Research and Treatment 47 235-253.
166. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM & Slawin KM 2002 Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. Journal of Clinical Oncology 20 833-841.
167. Shiry LJ, Blouin MJ, Lenhert S, Allan G & Pollak M 2002 Radiosensitizing effect of rhIGFBP-3 on MCF-7 breast cancer cells in vitro. Hormone Research 58 266 (abstract P20).
168. Siegel RA, Tolcsvai L & Rudin M 1988 Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). Cancer Research 48 4651-4655.
169. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C & Agarwal R 2002 Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Research 62 3063-3069.
170. Song BC, Chung YH, Kim JA, Lee HC, Yoon HK, Sung KB, Yang SH, Yoo K, Lee YS & Suh DJ 2001 Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer 91 2386-2393.
171. Stahl P, Kissau L, Mazitschek R, Giannis A & Waldmann H 2002 Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. Angewandte Chemie. International Edition in English 41 1174-1178.
172. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ & Roth RA 1988 Expression and characterization of a functional human insulin-like growth factor I receptor. Journal of Biological Chemistry 263 11486-11492.
173. Steller MA, Delgado CH, Bartels CJ, Woodworth CD & Zou Z 1996 Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Research 56 1761-1765.
174. Stewart CE & Rotwein P 1996 Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiological Reviews 76 1005-1026.
175. Szende B, Horvath A, Bokonyi G & Keri G 2003 Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. British Journal of Cancer 88 132-136.
176. Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G & Nagy A 2003 Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. International Journal of Oncology 22 1141-1146.
177. Taylor JE, Bogden AE, Moreau JP & Coy DH 1988 In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochemical and Biophysical Research Communications 153 81-86.
178. Torrisi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A, Ballardini B & Decensi A 2001 Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. British Journal of Cancer 85 1838-1841.
179. Twigg SM & Baxter RC 1998 Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. Journal of Biological Chemistry 273 6074-6079.
180. Ullrich A & Schlessinger J 1990 Signal transduction by receptors with tyrosine kinase activity. Cell 61 203-212.
181. Valentinis B, Bhala A, DeAngelis T, Baserga R & Cohen P 1995 The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Molecular Endocrinology 9 361-367.
182. Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB & Yee D 1997 Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. European Journal of Cancer 33 1108-1113.
183. van Roozendaal CE, Gillis AJ, Klijn JG, van Ooijen B, Claassen CJ, Eggermont AM, Henzen-Logmans SC, Oosterhuis JW, Foekens JA & Looijenga LH 1998 Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Letters 437 107-111.
184. Wakai K, Ito Y, Suzuki K, Tamakoshi A, Seki N, Ando M, Ozasa K, Watanabe Y, Kondo T, Nishino Y & Ohno Y 2002 Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Japanese Journal of Cancer Research 93 1279-1286.
185. Waksmanski B, Dudkiewicz J & Dabrowski S 2001 Function of insulin-like growth factor (IGF-I) and its binding protein (IGFBP-1) in pathological proliferation of endometrium. Wiadomosci Lekarskie 54 656-661.
186. Werner H & LeRoith D 1996 The role of the insulin-like growth factor system in human cancer. Advances in Cancer Research 68 183-223.
187. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM & Paraskeva C 2000 Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Research 60 22-27.
188. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO & Trichopoulos D 1998 Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. Journal of the National Cancer Institute 90 911-915.
189. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. PNAS 96 7324-7329.
190. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG & Oh Y 1999 Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140 1319-1328.
191. Yamauchi K & Pessin JE 1994 Insulin receptor substrate-1 (IRS1) and Shc compete for a limited pool of Grb2 in mediating insulin downstream signaling. Journal of Biological Chemistry 269 31107-31114.
192. Yu H & Rohan T 2000 Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92 1472-1489.
193. Yu H, Spitz MR, Mistry J, Gu J, Hong WK & Wu X 1999 Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. Journal of the National Cancer Institute 91 151-156.
194. Zadeh SM & Binoux M 1997 The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 138 3069-3072.
195. Zapf J 1995 Physiological role of the insulin-like growth factor binding proteins. European Journal of Endocrinology/European Federation of Endocrine Societies 132 645-654.
196. Zhang X & Yee D 2000 Tyrosine kinase signaling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Research 2 170-175.
197. Zi X, Zhang J, Agarwal R & Pollak M 2000 Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Research 60 5617-5620.